Gout Therapeutics Market, Size, Share 2021-2028
Added: (Wed Nov 10 2021)
Pressbox (Press Release) -
Market Overview
The Global Gout Therapeutics Market is expected to grow at a high CAGR of 8% during the forecasting period (2021-2028).
Gout s a type of inflammatory arthritis caused by the overabundance of uric acid in the body, either producing too much or excreting too little. Gout can be acute and chronic. Acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings ( known as tophi) can form on the joints made of uric acid and grow large, even breaking through the skin.
Download free sample: https://www.datamintelligence.com/download-sample/gout-therapeutics-market
Market Dynamics
The global gout therapeutics market is impacted by several factors such as the rising prevalence of gout globally due to change in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics.
Gout is the most common form of inflammatory arthritis, characterized by painful and disabling acute attacks. It is caused by hyperuricemia and the deposition of urate crystals in and around the joints. Long-standing untreated hyperuricemia can lead to chronic arthritis, joint damage, tophi formation, and urate nephropathy. According to the Australian Bureau of Statistics and National Health Survey 2017-2018, estimated that 187,000 Australians (0.8% of the population) suffer from gout conditions. Gout is more common in males than females; almost 9 in 10 (87%) people with gout are males. Gout treatment demand treatment is increasing, which is expected to show growth over the forecast period.
Besides, increasing government initiatives and awareness towards gout cause and treatment is expected to boost its growth. For instance, in May 2016, the Arthritis Foundation and Takeda Pharmaceuticals USA Inc. launched the Let’s Speak Gout program. Healthcare professionals and patients tool students to make more effective gouty arthritis management a priority.
In May 2018, Horizon Pharma plc marked Gout Awareness Day by launching Gout Revealed, which was created to spotlight real-life stories of people living with uncontrolled gout. People living with uncontrolled gout gets the opportunity to share their own story through the website, which will be updated throughout the year to help educate others.
Also, rising research and development to introduce new gout treatments drive the market's growth over the forecast period. For instance, on October 29th, 2019, Researchers at the Washington State University Health Sciences Spokane and elsewhere have identified a new therapeutic target for gout treatment. The research lays the foundation for developing new treatment strategies that could significantly improve the quality of life of millions of people worldwide who suffer from the condition. In the United States alone, gout affects an estimated 8.3 million people or about 4 percent of the population.
With the ongoing COVID-19 pandemic, several companies are testing their drugs for their treatment. For instance, on June 22nd, 2020, the anti-viral drug Favipiravir (Fabiflu) was approved to treat mild to moderate COVID-19 patients will be commercialized full scale in a week drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' to treat mild to moderate cases, which accounts for most COVID-19 infections.
However, the growth of the market is likely to hamper by side effects caused by grout drugs. For instance, the side effects of allopurinol include rash and low blood counts. Febuxostat side effects include rash, nausea, reduced liver function, and an increased risk of heart-related death. Corticosteroids' side effects may include mood changes, increased blood sugar levels, and elevated blood pressure.
Segment Analysis
– By Disease Type
• Acute Gout*
• Chronic Gout
– By Distribution Channel
• Hospital Pharmacies*
• Drug Stores
• Online Channels
• Others
Competitive Landscape
The gout therapeutics market is fragmented and highly competitive and consists of several major players. Few major players dominate the market share, and few emerging companies are expected to enter the market over the forecast period. Some of the market's major players market is Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, and Mylan. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, contributing to the Gout Therapeutics market's growth globally. For instance,
On March 2nd, 2020, Avion Pharmaceuticals launched Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.
In January 2020, US-based Novadoz Pharmaceuticals received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The approved product is AB-rated to the brand Uloric©, marketed by Takeda Pharmaceuticals America, Inc.
View Full Report: https://www.datamintelligence.com/research-report/gout-therapeutics-market
Enquiry Before Buying: https://www.datamintelligence.com/enquiry/gout-therapeutics-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com